πŸ‡ΊπŸ‡Έ FDA
Patent

US 10894052

Heterocyclic inhibitors of ATR kinase

granted A61KA61K31/5377A61P

Quick answer

US patent 10894052 (Heterocyclic inhibitors of ATR kinase) held by The Board of Regents of the University of Texas System expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/5377, A61P, A61P35/00